三官能性抗体
PMID 20073127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791310/.
↑ “The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor”. Cancer Research 69 (10): 4270–4276. (2009). doi:10.1158/0008-5472.CAN-08-2861. PMID 19435924.
↑ Reinhard, H (2011). “The effect of trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer”. Journal of Clinical Oncology 29 (suppl abstr 2601). http://abstract.asco.org/AbstView_102_82824.html.
↑ Ruf, P (2011). “Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites”.